Results 81 to 90 of about 5,115,827 (299)

Process integration in the optimisation of amidase production from recombinant Escherichia coli [PDF]

, 2008
Includes abstract.Includes bibliographical references (p. 127-138).This thesis presents the investigation of the production of a novel thermostable amidase (EC 3.5.1.4) from Geobacillus pallidus RAPc8 using recombinant E.coli BL21 (DE3).
Olaofe, Oluwafemi Ayokunle
core   +1 more source

Recombinant proteins in therapeutics: haemophilia treatment as an example

International Archives of Medicine, 2008
One of the most spectacular advances in the history of scientific knowledge was the discovery of deoxyribonucleic acid (DNA) by Watson and Crick in 1953. This enabled certain proteins to be prepared in this way for their therapeutic use in clinical practice.
openaire   +2 more sources

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

Automation of large scale transient protein expression in mammalian cells [PDF]

, 2011
Traditional mammalian expression systems rely on the time-consuming generation of stable cell lines; this is difficult to accommodate within a modern structural biology pipeline.
Susan Daenke, Jones, M, E. Yvonne Jones, Siebold, Christian, Daenke, Susan, Christian Siebold, Bishop, Benjamin, Margaret Jones, Clay, Jordan E, Stuart, David I., A. Radu Aricescu, Zhao, Y, Benjamin Bishop, Aricescu, Alexandru R, Radu Aricescu, A, Stuart, David, Yvonne Jones, E, Weixian Lu, Stuart, David I, Clay, JE, Daenke, S, Aricescu, Alexandru, Bishop, B, Jones, EY, Clay, Jordan E., Yuguang Zhao, Jones, Margaret, Lu, Weixian, David I. Stuart, Radu Aricescu, A., Yvonne Jones, E., Aricescu, AR, Jones, Edith, Jordan E. Clay, Zhao, Yuguang, Jones, E Yvonne, Lu, W, Siebold, C, Stuart, DI   +38 more
core   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Effects of post-translational modifications on prion protein aggregation and the propagation of scrapie-like characteristics in vitro [PDF]

, 2007
Prion diseases, or transmissible spongiform encephalopathies (TSEs) are typically characterised by CNS accumulation of PrPSc, an aberrant conformer of a normal cellular protein PrPC.
Oxley, David, Meersman, Filip, Webster, Judith, Kazlauskaite, Jurate, Pinheiro, Teresa J. T., Young, Duncan S., Dear, Denise V., Lowe, Christopher R., Gill, Andrew C., Bronstein, Igor   +9 more
core   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Highly tunable delivery of matrix-bound growth factors for therapeutic angiogenesis [PDF]

, 2014
Therapeutic angiogenesis is a promising strategy to treat pathologies characterized by insufficient blood supply to tissue, such as coronary and peripheral artery diseases, but also to promote the engraftment and survival of tissue-engineered constructs ...
Sacchi, Veronica
core   +1 more source

The market of therapeutic recombinant proteins to 2010

Journal of Commercial Biotechnology, 2004
Datamonitor's recombinant protein analytical framework shows that the sector with 77 marketed and 104 pipeline products will reach maturity undisturbed from potential biogeneric threat. It will see its value growing from US$35.8bn in 2004 to US$53bn in 2010 with a compound annual growth rate of no higher than 7 per cent.
openaire   +2 more sources

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source